Sign in to view content

Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2

Emily Y. Chew, MD

Video
Published 2023

Related

Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Updates from the Field
2024
Types of Strokes Seen in Patients
Sophie Jane Bakri, MD
Updates from the Field
2017

Category: Retinal Vascular Disease

See more